cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sangamo Therapeutics Inc
20 own
21 watching
Current Price
$0.5
$0.01
(2.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
106.41M
52-Week High
52-Week High
1.78000
52-Week Low
52-Week Low
0.29000
Average Volume
Average Volume
1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization106.41M
icon52-Week High1.78000
icon52-Week Low0.29000
iconAverage Volume1M
iconDividend Yield--
iconP/E Ratio--
What does the Sangamo Therapeutics Inc do?
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington's disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Read More
How much money does Sangamo Therapeutics Inc make?
News & Events about Sangamo Therapeutics Inc.
Business Wire
1 year ago
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest...
Zolmax
2years ago
DekaBank Deutsche Girozentrale boosted its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO Get Rating) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,900 shares of the biopharmaceutical ...
Ticker Report
2years ago
Equities analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO Get Rating) will post ($0.32) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sangamo Therapeutics earnings. The lowest ...
PR Newswire
2years ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty...
Zolmax
2years ago
StockNews.com began coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a hold rating on the biopharmaceutical companys stock. Other equities analysts have also recently ...
Frequently Asked Questions
Frequently Asked Questions
What is Sangamo Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Sangamo Therapeutics Inc shares?
plus_minus_icon
How can I buy Sangamo Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Sangamo Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Sangamo Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Sangamo Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Sangamo Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Sangamo Therapeutics Inc?
plus_minus_icon
What percentage is Sangamo Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Sangamo Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.5
$0.01
(2.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Mesoblast
Mesoblast
$6.15
$-0.07 (-1.13 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$3.39
$-0.02 (-0.59 %)
Gevo Inc
Gevo Inc
$0.60
$-0.06 (-9.61 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.38
$0.02 (1.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mesoblast
Mesoblast
$6.15
$-0.07 (-1.13 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$3.39
$-0.02 (-0.59 %)
Gevo Inc
Gevo Inc
$0.60
$-0.06 (-9.61 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.38
$0.02 (1.47 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00